Kiniksa Pharmaceuticals Ltd (KNSA)
Official siteHEALTHCARE • DRUG MANUFACTURERS - SPECIALTY & GENERIC • NASDAQ
Market Cap: $7.57B
Last updated: Nov 17, 2026 at 11:06 AM ET
Kiniksa Pharmaceuticals Ltd (KNSA) P/E Ratio & Valuation History
Kiniksa Pharmaceuticals (KNSA) trades at 72.5x trailing earnings and 7.8x sales. Its P/S of 7.8x is above its 5-year median of 4.7x. Its forward P/E is 60.6x. The median P/E across 10 similar companies is 19.9x.
Current Multiples
Its forward P/E is below its trailing P/E, which implies earnings per share about 19.6% higher over the next year. Its free cash flow yield is 2.7%.
| Multiple | Value |
|---|---|
| P/E (trailing) | 72.5x |
| Forward P/E | 60.6x |
| Price to sales | 7.8x |
| Price to book | 10.4x |
| EV/EBITDA | 49.2x |
| Price to FCF | 37.4x |
| EV/FCF | 36.9x |
| PEG | N/A |
| FCF yield | 2.7% |
Historical Medians
Against its 10-year medians, its P/B is 188.9% above 3.6x.
| Multiple | Current | 5-year median | 10-year median |
|---|---|---|---|
| P/S | 7.8x | 4.7x | N/A |
| P/B | 10.4x | 3.8x | 3.6x |
Valuation History
Over the 3 of the 8 year ends shown that have a P/E, its P/E ranged from 5.8x in 2022 to 97.4x in 2023.
| Year end | Price | P/E | P/S | P/B |
|---|---|---|---|---|
| 2025 | $41.25 | 55.7x | 4.6x | 5.7x |
| 2024 | $19.78 | N/A | 3.3x | 3.3x |
| 2023 | $17.54 | 97.4x | 4.6x | 2.9x |
| 2022 | $14.98 | 5.8x | 4.8x | 2.7x |
| 2021 | $11.77 | N/A | 21.0x | 4.4x |
| 2020 | $17.67 | N/A | N/A | 3.9x |
| 2019 | $11.06 | N/A | N/A | 2.7x |
| 2018 | $28.09 | N/A | N/A | 4.9x |
GNG Valuation
| GNG view | Overvalued |
|---|
GNG fair value is part of GNG Pro. See plans
Frequently Asked Questions About KNSA
What is KNSA's forward P/E ratio?
Kiniksa Pharmaceuticals has a forward P/E ratio of 60.6x.
Is KNSA stock overvalued?
GNG's valuation label for KNSA is Overvalued. Its P/E of 72.5x compares with a median of 19.9x across 10 similar companies.
What is KNSA's price to sales ratio?
Kiniksa Pharmaceuticals has a price to sales ratio of 7.8x.
KNSA pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors, Government Contracts